| 0.34 -0.065 (-16.03%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.95 | 1-year : | 1.34 |
| Resists | First : | 0.81 | Second : | 1.14 |
| Pivot price | 0.33 |
|||
| Supports | First : | 0.27 | Second : | 0.23 |
| MAs | MA(5) : | 0.41 |
MA(20) : | 0.32 |
| MA(100) : | 0.35  |
MA(250) : | 2.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.6 |
D(3) : | 15.9 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 32 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITOC ] has closed below upper band by 42.9%. Bollinger Bands are 53% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.4 - 0.4 | 0.4 - 0.4 |
| Low: | 0.33 - 0.34 | 0.34 - 0.34 |
| Close: | 0.35 - 0.36 | 0.36 - 0.36 |
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Wed, 13 May 2026
iTonic Holdings (ITOC) completes April 2026 private placement of new shares - Stock Titan
Tue, 28 Apr 2026
ITOC Investors Have Opportunity to Join iTonic Holdings Ltd. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Thu, 23 Apr 2026
iTonic Holdings (ITOC) Stock News & Updates - Stock Titan
Thu, 23 Apr 2026
Nasdaq grants iTonic (NASDAQ: ITOC) 180 days to meet bid price rule - Stock Titan
Thu, 23 Apr 2026
iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Yahoo Finance
Sat, 11 Apr 2026
Rosen Law Firm Encourages iTonic Holdings Ltd. Investors to Inquire About Securities Class Action Investigation – ITOC - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 9 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 299 (K) |
| Shares Short P.Month | 160 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | 0 % |
| Operating Margin | -682 % |
| Return on Assets (ttm) | -41 % |
| Return on Equity (ttm) | -71.3 % |
| Qtrly Rev. Growth | 91.5 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.98 |
| Price to Sales | 6.36 |
| Price to Cash Flow | -1.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|